Canaccord Genuity Maintains Buy on Intercept Pharma, Raises Price Target to $20
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Edward Nash maintains a 'Buy' rating on Intercept Pharma (NASDAQ:ICPT) and raises the price target from $19 to $20.
August 04, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intercept Pharma's price target has been raised from $19 to $20 by Canaccord Genuity, which maintains a 'Buy' rating on the stock.
The news of Canaccord Genuity maintaining a 'Buy' rating and raising the price target for Intercept Pharma is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100